AlphAIAlphAI — Financial news for AI agents
stocktitan.netOCT 232 min read$EVAX

Six melanoma responders received Evaxion's vaccine alone in year three. None had tumor progression.

Evaxion A/S (NASDAQ: EVAX) reported three-year data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. All six patients in the trial's extension showed no tumor progression, maintaining responses seen at two years. The data will be presented at ESMO 2026. EVX-01 induced an immune response in all patients, with 89% of vaccine neoantigens generating potent T-cell responses.

Original reporting
stocktitan.net
Published Oct 23, 2026, 6:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 6:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$EVAX
Bullish
high confidence
Mentioned
$EVAX
Relevance
9/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$EVAXBullishMed
01

Why it matters

The three‑year data provides the first durability evidence for EVX-01, potentially de‑risking the program and supporting future fundraising or partnership discussions.

02

Market read

First disclosure of durable Phase 2 data for a personalized cancer vaccine, likely to move EVAX and influence peer biotech valuations.

03

What to watch

Cash runway extends only to H2 2027; financing needs for later‑stage trials could pressure the share price.

Relevance 9/10Novelty 9/10Timing: today

Background

Evaxion is a clinical‑stage TechBio company using AI‑Immunology™ to develop personalized cancer vaccines. The EVX-01 vaccine is its lead asset.

Company-level read

Ticker impact

$EVAXBullishHigh confidence
Context

Evaxion disclosed three-year Phase 2 trial data for its melanoma vaccine EVX-01, showing sustained immune responses and no tumor progression.

Expected impact

upward pressure as investors price in durable efficacy

Evidence & confidence

First report of durable three‑year results; trial shows 100% immune response and no progression, likely to boost valuation.

Market effects

Sector

Strengthens confidence in personalized cancer vaccine platforms, may benefit peer biotech firms developing neoantigen vaccines.

Regional

Positive for Copenhagen‑based biotech sector and broader European biotech indices.

Global

Adds to global pipeline momentum for AI‑driven immunotherapies.

Counterpoint

What could challenge this read

If longer‑term efficacy or safety concerns emerge, the hype could fade and the stock may face sell‑off.

Key entities

  • company
    Evaxion A/S

    NASDAQ‑listed biotech developing AI‑driven immunotherapies.

  • individual
    Professor Muhammad Adnan Khattak

    Key opinion leader and trial investigator presenting the data.

Read at source← All news

StoryEvaxion reports three-year durability and immune data for melanoma vaccine

Also covered by

1 outlet

Related articles

OCT 23
$EVAXMedAI 8/10

Evaxion reports three-year data for cancer vaccine EVX-01

Evaxion A/S (EVAX) reported three-year phase 2 trial data for its cancer vaccine EVX-01, showing sustained immune response and no tumor progression in advanced melanoma patients. The data will be presented at the ESMO Congress 2026. EVX-01 is personalized and designed using Evaxion's AI-Immunology platform. The company has a cash runway into mid-2027.

investing.com2 min
OCT 19
$EVAXHighAI 8/10

Evaxion stock surges on 3-year melanoma vaccine trial data

Evaxion AS ADR (EVAX) shares rose 21.6% after reporting 3-year data from its EVX-01 phase 2 trial in advanced melanoma patients. All patients maintained clinical responses with no tumor progression. The data will be presented at ESMO Congress 2026. EVX-01 is a personalized cancer vaccine developed using AI-Immunology platform.

investing.com2 min
OCT 19
$EVAXMedAI 8/10

Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion A/S (NASDAQ: EVAX) reported sustained clinical responses for all patients at three-year follow-up in a phase 2 trial for its personalized cancer vaccine EVX-01 in advanced melanoma. The data, to be presented at ESMO 2026, showed a 75% objective response rate with 25% of patients achieving complete response. EVX-01 will be discussed in a webinar and poster session.

finanznachrichten.de2 min
OCT 19
$EVAXMedAI 8/10

Evaxion Reports Durable Three-Year Responses With EVX-01 In Advanced Melanoma

Evaxion A/S reported that patients in a Phase 2 study of its personalized cancer vaccine EVX-01 for advanced melanoma maintained responses for three years, with no tumor progression. The company will present the data at ESMO 2026, showing a 75% response rate and 92% clinical benefit at two years. EVX-01 is currently in development for advanced solid tumors. EVAX stock closed at $2.83 on October 16, 2026, and is up 2.83% in pre-market trading.

rttnews.com2 min